Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder
| Autor: | Kristen Focht, Cecelia P. Kane, Lee S. Cohen, Claudio N. Soares, Michael E. Thase, Phil Ninan, Susan G. Kornstein, Qin Jiang, Christine J. Guico-Pabia, Anita H. Clayton |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.medical_specialty Serotonin reuptake inhibitor Blood Pressure Citalopram Weight Gain Double-Blind Method Liver Function Tests Internal medicine Desvenlafaxine Succinate mental disorders medicine Escitalopram Humans Neurotransmitter Uptake Inhibitors Psychiatry Aged Depressive Disorder Major business.industry Obstetrics and Gynecology Hamilton Rating Scale for Depression Middle Aged medicine.disease Cyclohexanols Desvenlafaxine Postmenopause Tolerability Major depressive disorder Female business Reuptake inhibitor Sleep Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Menopause (New York, N.Y.). 17(4) |
| ISSN: | 1530-0374 |
| Popis: | Objective: This study assessed the efficacy, safety, and tolerability of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine and the selective serotonin reuptake inhibitor escitalopram for major depressive disorder (MDD) in postmenopausal women. Methods: In this randomized, double-blind study, postmenopausal outpatients (aged 40-70 y) with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition MDD received flexible-dose desvenlafaxine (100-200 mg/d) or escitalopram (10-20 mg/d) for 8 weeks. Acute-phase responders, that is, women with a 50% or greater reduction from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D 17 ) total score, were eligible to continue the same double-blind treatment in the 6-month continuation phase. The primary efficacy outcomes were mean change from baseline in HAM-D 17 total score (acute phase), analyzed using a mixed-effects model for repeated measures, and the proportion of women who maintained response (continuation phase), analyzed using logistic regression. Results: Reductions in HAM-D 17 total score at acute-phase endpoint were similar for desvenlafaxine- and escitalopram-treated women (—13.6 vs —14.3, respectively; P = 0.24). No significant difference was observed between groups at continuation-phase endpoint in the proportion of women who maintained response (desvenlafaxine, 82%; escitalopram, 80%; P = 0.70). In both phases, desvenlafaxine and escitalopram were generally safe and well tolerated. Conclusions: Among postmenopausal outpatients with MDD, there were no significant differences in the efficacy of desvenlafaxine and escitalopram based on primary efficacy analyses. The results do not support the overall hypothesis that the serotonin-norepinephrine reuptake inhibitor desvenlafaxine has an efficacy advantage for the treatment of MDD in postmenopausal women because, in this particular subgroup, desvenlafaxine failed to prove superiority over escitalopram. Safety and tolerability were comparable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|